Indications and Orphan Designations

Impavido is the first and only FDA-approved drug to treat cutaneous or mucosal leishmaniasis, in addition to Viceral leishmaniasis.

 

Impavido (Miltefosine) is promising with an orphan designation for the treatment of free-living ameba (FLA) infections caused by Naegleria fowleri, Balamuthia mandrillaris, Amebiasis, Schistosomiasis, Granulomatous Amebic
Encephalitis (GAE) and Acanthamoeba species. Use of Impavido with these Orphan Designations is considered "off-label" use at this time.

 

Please contact us to learn more 

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO 

®

Contact Your Doctor or the CDC to Learn More about IMPAVIDO (miltefosine)

Impavido is a registered trademark of Knight Therapeutics Licensed exclusively to Profounda in the USA

© 2015 Profounda, Inc. 

For Emergencies
Call 911